How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combination-bupropion-nrts.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Combination Bupropion + NRTs — Competitive Intelligence Brief

Combination Bupropion + NRTs (Combination Bupropion + NRTs) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidepressant + nicotine replacement combination. Area: Addiction Medicine / Smoking Cessation.

marketed Antidepressant + nicotine replacement combination Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule Live · refreshed every 30 min

Target snapshot

Combination Bupropion + NRTs (Combination Bupropion + NRTs) — Brentwood Biomedical Research Institute. Bupropion inhibits norepinephrine and dopamine reuptake while nicotine replacement therapies provide exogenous nicotine to reduce withdrawal symptoms, together addressing both the neurochemical and behavioral aspects of tobacco dependence.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Combination Bupropion + NRTs TARGET	Combination Bupropion + NRTs	Brentwood Biomedical Research Institute	marketed	Antidepressant + nicotine replacement combination	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
bupropion + lozenge	bupropion + lozenge	University of Wisconsin, Madison	marketed	Antidepressant + nicotine replacement therapy	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidepressant + nicotine replacement combination class)

Brentwood Biomedical Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Combination Bupropion + NRTs — Competitive Intelligence Brief. https://druglandscape.com/ci/combination-bupropion-nrts. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab